|
IM-MV 20-010_000
|
Erasmus MC
|
MVA-MERS-S_DF1: An MVA-vectored vaccine candidate against MERS coronavirus, encoding the MERS spike protein
|
02-11-2020
|
Vergunning verleend
|
|
IM-MV 20-012_000
|
Het Nederlands Kanker Instituut
|
Trials to assess safety, tolerability and recommended phase 2 dose (RP2D) of NY-ESO-1 and LAGE-1a specific T cells, alone or in combination with other agents, in HLA-A*02+ participants with NY-ESO-1 and/or LAGE-1a positive advanced tumors
|
13-11-2020
|
Vergunning verleend
|
|
IM-MV 20-013_000
|
Het Nederlands Kanker Instituut
|
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9–Engineered T Cells (CTX130) in Adult Subjects with Malignancies
|
09-11-2020
|
Vergunning verleend
|
|
IM-MV 20-014_000
|
LUMC
|
A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease
|
|
Vergunning verleend
|
|
IM-MV 20-016_000
|
LUMC
|
Application of iPSC-derived clinical products to replace or restore the function of cells, tissues and/or organs affected by disease, ageing or trauma
|
|
Ontwerpbesluit genomen
|
|
IM-MV 20-017_000
|
LUMC
|
Phase I/II study of lentiviral gene transfer for SCID-X1
|
|
Ontwerpbesluit genomen
|
